Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Net Margin (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Net Margin for 4 consecutive years, with 14.61% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 1496779.0% to 14.61% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28.69% through Dec 2025, up 7871.0% year-over-year, with the annual reading at 28.69% for FY2025, 4577.0% up from the prior year.
  • Net Margin hit 14.61% in Q4 2025 for Axsome Therapeutics, up from 27.62% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 11.88% in Q1 2023 to a low of 14982.4% in Q4 2024.
  • Historically, Net Margin has averaged 1115.85% across 4 years, with a median of 91.14% in 2024.
  • Biggest five-year swings in Net Margin: crashed -1484448bps in 2024 and later skyrocketed 1496779bps in 2025.
  • Year by year, Net Margin stood at 251.29% in 2022, then skyrocketed by 45bps to 137.92% in 2023, then plummeted by -10763bps to 14982.4% in 2024, then skyrocketed by 100bps to 14.61% in 2025.
  • Business Quant data shows Net Margin for AXSM at 14.61% in Q4 2025, 27.62% in Q3 2025, and 31.95% in Q2 2025.